409 related articles for article (PubMed ID: 11833835)
1. Bivalirudin: a direct thrombin inhibitor.
Gladwell TD
Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
Carswell CI; Plosker GL
Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
[TBL] [Abstract][Full Text] [Related]
3. Pharmacology and clinical use of bivalirudin.
Sciulli TM; Mauro VF
Ann Pharmacother; 2002 Jun; 36(6):1028-41. PubMed ID: 12022907
[TBL] [Abstract][Full Text] [Related]
4. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
Chew DP
Hamostaseologie; 2002 Aug; 22(3):60-6. PubMed ID: 12215763
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin: a new approach to anticoagulation.
Nawarskas JJ; Anderson JR
Heart Dis; 2001; 3(2):131-7. PubMed ID: 11975781
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of bivalirudin.
Reed MD; Bell D
Pharmacotherapy; 2002 Jun; 22(6 Pt 2):105S-111S. PubMed ID: 12064567
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.
White HD; Chew DP
Expert Opin Pharmacother; 2002 Jun; 3(6):777-88. PubMed ID: 12036417
[TBL] [Abstract][Full Text] [Related]
8. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
Antman EM; McCabe CH; Braunwald E
Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Ramana RK; Lewis BE
Vasc Health Risk Manag; 2008; 4(3):493-505. PubMed ID: 18827868
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin in percutaneous coronary intervention.
Caron MF; McKendall GR
Am J Health Syst Pharm; 2003 Sep; 60(18):1841-9. PubMed ID: 14521034
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Lincoff AM; Kleiman NS; Kottke-Marchant K; Maierson ES; Maresh K; Wolski KE; Topol EJ
Am Heart J; 2002 May; 143(5):847-53. PubMed ID: 12040347
[TBL] [Abstract][Full Text] [Related]
12. Direct antithrombins: mechanisms, trials, and role in contemporary interventional medicine.
Wong CK; White HD
Am J Cardiovasc Drugs; 2007; 7(4):249-57. PubMed ID: 17696566
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.
Seybert AL
Pharmacotherapy; 2002 Jun; 22(6 Pt 2):112S-118S. PubMed ID: 12064568
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention.
Moen MD; Keating GM; Wellington K
Drugs; 2005; 65(13):1869-91. PubMed ID: 16114983
[TBL] [Abstract][Full Text] [Related]
15. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
17. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.
White H;
Lancet; 2001 Dec; 358(9296):1855-63. PubMed ID: 11741625
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
19. Bivalirudin: pharmacology and clinical applications.
Shammas NW
Cardiovasc Drug Rev; 2005; 23(4):345-60. PubMed ID: 16614733
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
